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Activation of the TNF-related apoptosis-inducing ligand (TRAIL) pathway can induce apoptosis in a broad
range of human cancer cells. Fourmembrane-bound receptors have been identiﬁed. TRAIL-R1 and TRAIL-
R2 contain a functional death domain; TRAIL-R3 and TRAIL-R4 lack a functional death domain and
function as decoy receptors. Flow-cytometric analysis revealed that acutemyeloid leukemic (AML) blasts
expressed signiﬁcantly more pro-apoptotic receptors compared to normal blasts. However, about 20% of
AML patients highly expressed decoy receptor TRAIL-R3, which was strongly correlated to a shortened
overall survival. TRAIL-R3 expressionwas also high onCD34+/CD38− cells, the compartment that harbors
the leukemia initiating stem cell. Expression levels of pro-apoptotic TRAIL receptors were not correlated




Cell death could be enhanced by down-modulation of TRAIL-R3, conﬁrming its decoy function on AML
blasts. Bypassing of TRAIL-R3 by treatmentwith antibodies directly targeting TRAIL-R2 resulted in higher
rates of induced cell death (max. 80%).





Since chemotherapy and stem cell transplantation can only
ure approximately 30% of patients with acute myeloid leukemia
AML), there is urgent need for complementary and targeted treat-
ent modalities. Use of recombinant TRAIL (TNF (tumor necrosis
actor)-related apoptosis-inducing ligand) could be included in the
reatment of AML patients. Lymphocytes, NK cells, dendritic cells
nd monocytes are able to upregulate membrane bound TRAIL
mTRAIL) and to secrete a soluble formof TRAIL (sTRAIL) after stim-
lation with interferons or IL-2 [1–4]. In human, four membrane
ound receptors for mTRAIL and sTRAIL have been identiﬁed: two
f themTRAIL-R1 (formerly knownasDR4) and TRAIL-R2 (formerly
nown as DR5) contain a functional death domain and are capable
f initiating the apoptotic cascade, while two others TRAIL-R3 (for-
erly known as DcR1) and TRAIL-R4 (formerly known as DcR2)ack a functional death domain and function as decoy (antagonis-
ic) receptors. Binding of TRAIL to one of the functional receptors
RAIL-R1 (R1) or TRAIL-R2 (R2) results, after clustering, in the for-
ation of aDeath-Inducing Signalling Complex (DISC) consisting of
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oi:10.1016/j.leukres.2010.12.032gniﬁcant shortened overall survival. AML blasts could be targeted by anti-
a new therapeutic option for AML patients.
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TRAIL, its receptor, the FAS associated death domain adaptor pro-
tein (FADD) and caspase 8 [5,6]. Activated caspase 8 can directly
activate caspase 3 leading to apoptosis and also, by cleaving Bid,
activate the mitochondria-intrinsic pathway [7]. Binding of TRAIL
to a decoy receptor will not induce apoptosis. TRAIL-R3 (R3) and
TRAIL-R4 (R4) inhibit TRAIL induced apoptosis in distinct ways. R3
is a glycosyl-phosphatidy-linositol (GPI) linked protein and lacks
an intracellular domain [8]. The death domain of R4 is truncated.
R3 prevents TRAIL-R2-DISC assembly, while R4 impairs DISC pro-
cessing to caspase activation [9].
Several important functions for TRAIL induced apoptosis have
been reported. First, TRAIL mediated cytotoxicity plays an impor-
tant role in innate and adaptive immune responses [10]. Second,
TRAIL exerts a regulatory function on erythroid and myeloid mat-
uration in normal hematopoiesis [11–14]. Moreover, senescent
neutrophils are eliminated by TRAIL induced apoptosis upon their
return to the bonemarrow [15]. Finally, andmost intensively stud-
ied, TRAILhas an important function in tumor immunesurveillance.
TRAIL deﬁcient mice are more susceptible to tumor development
and metastasis [16]. Inhibition of TRAIL induced apoptosis by
administration of a neutralizing antibody leads to tumor progres-
sion in mice [17]. Recombinant soluble TRAIL (rsTRAIL) constructs
are able to induce apoptosis in many cancer cell lines (reviewed in
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een the observation that normal cells mostly express the decoy
eceptors R3 and R4,whilemany tumor cells express the functional
eceptors R1 and R2 (reviewed in [19]).
Studies on TRAIL receptor expression onmyeloid leukemic cells
nd clinical outcome of AML patients did not reveal a correla-
ion between receptor expression and prognosis [20]. Moreover,
ow sensitivity of leukemic blasts to rsTRAIL has been reported
21–23]. This could be either due to a relative high expression of
he decoy receptors on the cell surface or to intracellular high lev-
ls of anti-apoptotic proteins or low expression of pro-apoptotic
roteins. Indeed, pre-treatment of leukemic cells with sensitizing
gents (kinase inhibitors, triptolide, chemotherapy) increases the
usceptibility to rsTRAIL [24–28].
An alternative strategy to employ the TRAIL pathway could be to
ircumvent the decoy receptor expression by directly targeting the
ro-apoptotic receptors R1 and R2 by selective antibodies [29–32].
hese antibodies have entered phase I and phase II clinical trials
reviewed by Ashkenazi and Herbst [33]).
In this studywe explored the possible applications of employing
he TRAIL pathway in therapy regimens for patients with AML. We
nalyzed the receptor expression on hematopoietic precursor cells
f a large cohort of AML patients, compared them to expression
evels of healthy donors, and correlated them to clinical outcome.
e have found that a high expression of the decoy receptor R3was
orrelated to a poor clinical outcome. Also, decoy function of R3
as conﬁrmed in vitro by treating leukemic cells lines and fresh
rimary AML samples with rsTRAIL or with antibodies directly tar-
eting R1 andR2. By conﬁrming the decoy function of R3 inmyeloid
eukemic cells and by demonstrating highest levels of cell death
fter targeting R2, we have found new evidence for directly tar-
eting the pro-apoptotic receptors as an option in the treatment of
ML patients.
. Materials and methods
.1. Patients’ samples
After informed consent and according to the Helsinki declaration, blood and
one marrow samples were collected from 92 patients with de novo AML and
rom 11 healthy donors. Patients were classiﬁed according to the French-American-
ritish (FAB)-classiﬁcation [34]. Patients received therapy according to HOVON
Dutch-Belgian Hematology-Oncology Cooperative Group) protocols (available at
ww.hovon.nl). Patients received two cycles of chemotherapy (containing cytara-
in, combined with idarubicin or amsacrine) followed by autologous stem cell
ransplantation or a third cycle of chemotherapy (mitoxantrone and etoposide).
atients with promyelocytic leukemia (FAB-M3) were treated differently and were
xcluded from this study. Cytogenetic risk group was determined as favorable
translocation(8;21), or inv(16)), standard (neither favorablenor adverse) or adverse
complex karyotype, -5 or -7, deletion(5q), abnormality(3q), t(6;9), t(9;22) or abnor-
ality 11q23). Overall survival (OS) was deﬁned as the time period between date
f diagnosis and either date of death or last date of follow-up. Disease free survival
DFS) was deﬁned as the time period between achievement of complete remission
CR) and eithermoment of relapse or last date of follow up in non-relapsed patients.
Bone marrow mononuclear cells from patients and healthy donors were col-
ected through density gradient centrifugation (Ficoll-PaqueTMPLUS, Amersham
iosciences). Samples were analyzed immediately or cryopreserved in liquid nitro-
en until analysis.
.2. Flow cytometry analysis
The following mouse antibodies were used: unlabeled anti-TRAIL (clone 5D5),
nti-TRAIL-R1 (clone HS101), anti-TRAIL-R2 (clone HS201), anti-TRAIL-R3 (clone
S301) andanti-TRAIL-R4 (cloneHS402) all fromAlexis (Lausen, Switzerland).Unla-
eled IgG1 isotype (Beckton Dickinson, (BD, New Jersey, USA)); FITC labeled CD34
nd CD38 (BD); PercP labeled CD45 (Beckman Coulter, Fullerton, USA); APC labeled
D34 and CD38 (BD).
Mononuclear cell fractions were preincubated with 10% human gammaglob-
line (6mg/ml, Sanquin, the Netherlands) followed by incubation with directly
abeled antibodies. For TRAIL and TRAIL receptor detection, cells were incubated
ith the unlabeled antibodies and subsequently with PE-conjugated rabbit-anti-
ouse immunoglobulin (Dako, Glostrup, Denmark). A mixture of non-relevant
ouse antibodies of different isotypes was added to avoid aspeciﬁc binding of
ubsequently directly labeled antibodies. All incubations were performed at roomResearch 35 (2011) 741–749
temperature during 15min. Cells were washed after every incubation step with
PBS/0.1% BSA/0.05% sodiumazide and analyzed on a FACS Calibur (BD). 25,000 living
cells on a forward scatter were analyzed using CellQuest software (BD).
Cell viability was measured by combined AnnexinV (VPS diagnostics, Hoeven,
The Netherlands) and 7AAD staining (Via-Probe, BD Pharmingen). Absolute cell
numbers were counted by using beads (ﬂow-countTM ﬂuorospheres, Beckmann
Coulter).
2.3. Apoptosis induction of cell lines and fresh AML samples with sTRAIL/Apo2L
and mapatumumab and lexatumumab
The cell linesMM6 (ACC124), Kasumi-1 (ACC220) andME1 (ACC537)were pur-
chased fromDSMZ.Cell linesU937 (CRL-1593.2),HL60 (CCL-240),KG1-a (CCL-246.1)
and THP1 (TIB-202) were purchased from ATCC. sTRAIL/Apo2L was kindly provided
by Amgen/Genentech. Agonistic fully human monoclonal antibodies speciﬁc for
TRAIL-R1 (mapatumumab, formerly HGS-ETR1) and TRAIL-R2 (lexatumumab, for-
merlyHGS-ETR2)werekindlyprovidedbyHumaneGenomeSciences, Inc (Rockville,
MD, USA).
250,000 cells from indicated cell lines and from patient sampleswere incubated
in 500l in 48 wells ﬂat bottom plates with different concentrations sTRAIL/Apo2L
(10, 100, 300 and 1000ng/ml) for different time periods (2, 4, 8, 18, 24 and 48h)
at 37 ◦C in a humidiﬁed incubator. Optimal conditions for apoptosis induction in
cell lines with sTRAIL/Apo2L were found after 18h at 37 ◦C at a concentration of
100ng/ml sTRAIL/Apo2L (data not shown).
Fresh AML patient samples were incubated for 18h at 37 ◦C, with different
concentrations of sTRAIL/Apo2L, mapatumumab and lexatumumab. All cells were
cultured in RPMI supplementedwith 10% fetal calf serum (FCS), except for theMM6
cell linewhichwas cultured in specialmedium [35]. In someexperiments, cellswere
pretreatedwith the pancaspase inhibitor Z-Val-Ala-DL-Asp-ﬂuoromethylketone (z-
VAD) (Alexis, 10mol ﬁnal concentration) for 30min. Absolute viable cells were
deﬁned by AnnexinV and 7AAD negativity and counted by using ﬁxed amounts of
beads in every sample.
2.4. Modulation of cell surface R3 expression
To remove R3, which is a GPI linked protein, we used phosphatidyl-inositol
phospholipase C (PI-PLC) (Molecular Probes (Eugene, USA)). To optimize R3 removal
we tested various PI-PLC concentrations (0.5 and 3.0g/ml) and various incubation
times, temperatures (20min at a rock plate at 4 ◦C, 1 and 4h at 37 ◦C), and media
(PBS, RPMI/10% FCS for HL60, for MM6 special medium (see above)). Moreover, we
addeddifferent concentrations (0.5, 1 and 10g/ml) of cycloheximide (CHX, (Sigma,
St Louis, USA)) to prevent de novo synthesis of R3. Incubationwith PI-PLC 0.5g/ml,
for 4h at 37 ◦C in RPMI/10% FCS or MM6 medium yielded best results.
Addition of CHX induced additional apoptosis in all cultures. Control experi-
ments without CHX showed no re-synthesis of cell surface R3 after 24h, so CHX
was withdrawn in subsequent experiments from cultures. After treatment with PI-
PLC, cells were directly incubated for 18h with sTRAIL/Apo2L, mapatumumab or
lexatumumab.
2.5. Statistical analyses
Statistical analyses were conducted with SPSS software program (version
15.0). To analyze associations between variables Spearman’s correlation coefﬁ-
cient was used. Differences between patient characteristics were analyzed with
Mann–Whitney U test. Paired samples t-test was used to measure differences in
induced apoptosis in cell lines. For survival data, Kaplan–Meier curves were con-
structed and compared by means of the log-rank test. To explore the simultaneous
effect of several variables on survival the Cox regression model was used.
3. Results
3.1. TRAIL receptor expression on myeloid leukemic blasts and
correlation to clinical outcome
Patient characteristics are shown in Table 1 and reﬂect a repre-
sentative AML patient group.Mean follow-up of all patientswas 32
months (range 0–158, median 11 months). 18 patients (20%) did
not achieve CR during induction therapy. A signiﬁcant difference
between patients achieving CR or not was observed in white blood
cell count (WBC) at diagnosis (p=0.001). 6 of 7 (86%) patients with
a favorable cytogenetic risk group achieved CR versus 5 of 16 (31%)
patientswith an unfavorable cytogenetic risk group (difference not
signiﬁcant due to small groups).
Myeloid leukemic blasts were deﬁned by CD45dim and CD34+
expression. A representative example of the gating strategy for
TRAIL receptor expression levels on AML blasts and on bone mar-




eig. 1. Example of gating strategy for the analysis of TRAIL receptor expression levels on
iving cells by CD45dim and CD34+ expression. TRAIL receptor expression levels were deﬁ
ig. 2. TRAIL-receptor expression onmyeloid leukemic blasts of 92 patients with de novo
xpression. Horizontal bars indicate mean expression levels.bone marrow of AML patients and healthy donors. Blasts were deﬁned in a gate of
ned as compared to the isotype control.
AML and of 11 healthy donors. Myeloid blasts were deﬁned by CD45dim and CD34+
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Table 1
Characteristics of 92 patients with de novo AML. Patients were classiﬁed according




Age in years at diagnosis, median (range) 48 (16–65)
WBC at diagnosis, median (range) 43 (1–300)
Follow-up in months, mean (range) 32 (1–160)
Disease free survival in months, mean (range) 35 (1–158)
Complete remission rate, number (%)* 74 (80)
Fab classiﬁcation, number (%)
AML M0 6 (6)
AML M1 13 (14)
AML M2 20 (22)
AML M4 24 (26)
AML M5 24 (26)
AML M6 2 (2)
RAEB-t 2 (2)
Not classiﬁed 1 (1)










































higher on the CD38− as compared to the CD38+ compartment,
see Fig. 5A. When analyzing the ratio (of pro- and anti-apoptotic
receptors), CD34+/CD38− cells expressed signiﬁcantly more anti-
apoptotic receptors as compared to CD34+/CD38+ cells (p=0.023,
seeFig. 5B). Thisdifferencewasalso seenonblastsofhealthydonorsNot done 2 (2)
* A signiﬁcant difference between patients either or not achieving CR was
bserved in white blood cell count (WBC) at diagnosis (p=0.001).
owderivedblasts of healthydonors is provided in Fig. 1. In contrast
o earlier reports on TRAIL receptor expression levels [23], we have
redominantly found (pro-apoptotic) R1 and R2 expression (mean
ercentage positive cells 16% and 34%, range 0–79% and 0–97%
espectively) versus (anti-apoptotic) R3 and R4 expression (mean
% and 10%, range 0–71% and 0–45%) on myeloid leukemic blasts
Fig. 2). When compared to normal blasts, AML blasts had sig-
iﬁcantly higher expression of R1 and R2 (p=0.001 and p=0.006
espectively) and signiﬁcantly lower expression of R3 (p=0.006).
4 expressiondidnotdiffer betweenAMLandnormalblasts (Fig. 2).
Althoughmean expression of R3 on AML blasts is lower than on
ealthydonors, Fig. 2 shows that 20%ofpatientshaveR3expression
bove mean plus 1 standard deviation (SD) (19%=mean normal
xpression (13%) plus SD (6%)). 10% of patients have a higher R3
xpression than mean+2SD (=25%).
We determined a pro- or anti-apoptotic proﬁle of leukemic
lasts by dividing the percentage of positive leukemic blasts
or R1 and R2 by the percentage positive blasts for R3 and R4
R1+R2)/(R3+R4). When comparing healthy donors and AML
atients, blasts from AML patients revealed a signiﬁcantly higher
atio and thus a higher pro-apoptotic receptor proﬁle than healthy
onors (p<0.005, Fig. 3).
In a univariate analysis, none of the expression levels of the
RAIL receptors was correlated to achievement of complete remis-
ion (CR). Furthermore, in univariate analysis, the percentage of R1,
2 and R4 positive blasts did not correlate to OS (p=0.6, p=0.2 and
=0.2)) or DFS (p=0.2, p=0.5 and p=0.3 respectively). On the other
and, the percentage of the anti-apoptotic R3 positive blasts sig-
iﬁcantly correlated to OS (p=0.036) and to DFS (p=0.04). Patients
n which >25% (mean normal value +2SD) of leukemic blasts were
ositive for R3 had a signiﬁcantly shortened OS (p=0.002), as
emonstrated in a Kaplan–Meier curve (Fig. 4).
In a multiple regression model (Cox), high R3 expression was
he most signiﬁcant prognostic factor for OS next to age at diagno-
is (p=0.003 vs. p=0.03, respectively). WBC was not a signiﬁcant
rognostic factor (p=0.174). As the patient groups with a poor and
avorable risk proﬁle were small (n=7 and n=16 respectively), we
ould not include cytogenetic risk proﬁle as a separate variable in a
egression analysis. Therefore, we performed a regression analysis
n the patient groupwith an intermediate risk proﬁle (n=53). WBCFig. 3. Pro-apoptotic and anti-apoptotic proﬁles of leukemic blasts from 92 de novo
AML patients and 11 healthy donors determined by dividing the percentage of pos-
itive leukemic blasts for R1 and R2 by the percentage positive blasts for R3 and R4
(R1+R2)/(R3+R4), the TRAIL index. Horizontal bars indicate mean levels.
was also in the intermediate cytogenetic risk groupnot a signiﬁcant
predictor (p=0.128). In patients with an intermediate cytogenetic
risk proﬁle, high R3 expression was a better predictive parameter
for OS (p=0.007) than age (p=0.038).
In conclusion, although leukemicblastsdidexpresshigher levels
of pro-apoptotic R1 and R2 than normal blasts, these clinical data
suggest that simultaneously expressed anti-apoptotic R3 strongly
inﬂuences OS.We hypothesize that high expression of R3 prohibits
effective apoptosis by naturally occurring nativemTRAIL or sTRAIL.
3.2. TRAIL receptor expression on the leukemic CD34+CD38−
stem cells
In CD34 positive (CD34+) AML, the leukemia-initiating event
originates from the CD34+/CD38− stem cell compartment. Survival
of these cells after chemotherapymay lead tominimal residual dis-
ease (MRD) and subsequently to relapse. In AML patients, a high
percentage of CD34+CD38− stem cells at diagnosis signiﬁcantly
correlated with a high MRD frequency after chemotherapy and
directly correlated with poor survival [36]. It is generally accepted
that treatment of AML should aim to target the leukemic stem
cell. We analyzed the TRAIL receptor expression directly on the
CD34+/CD38− compartment of 14 AML patients and 4 healthy
donors. The higher pro-apoptotic receptor proﬁle of AML blasts
when compared to normal blasts was conﬁrmed in these groups
(data not shown). When comparing the CD34+CD38− cells to the
CD34+CD38+ cells, in AML patients the expression of TRAIL R3 wasFig. 4. Kaplan–Meier survival curve of 92 de novo AML patients. Patients in which
>25% (mean normal value +2SD) of leukemic blasts were positive for R3 had a sig-
niﬁcantly shortened OS (p=0.002 log rank).























cig. 5. (A) Example of theTRAIL-R3 expression on CD34+/CD38− blasts of an AML p
eukemic stem cells) blasts as compared to CD34+/CD38+ blasts. (B) Pro-apoptotic
one on the CD34+/CD38− compartment and compared to the CD34+/CD38+ comp
or R1 and R2 by the percentage positive blasts for R3 and R4 (R1+R2)/(R3+R4), th
ut was not statistically different on these blasts. Probably, nor-
al but especially leukemic stem cells are assigned to prevent
hemselves to TRAIL induced apoptosis by higher decoy receptor
xpression.
In conclusion, both the clinical correlation between high R3
xpression and worse survival and the relative high expression of
nti-apoptotic receptors on leukemic stem cells suggest a possible
ole for decoy receptor R3 in causing immune-escape of leukemic
lasts.
.3. TRAIL receptor expression on leukemic cell lines and in vitro
TRAIL/Apo2L induction before and after modulation of R3
The functionofR3asadecoy receptorhasbeenclearly addressed
n Jurkat cells (T cells), HeLa (human adenocarcinoma), and 293
human embryonic kidney) cell lines [37], but never on human
yeloid cells. To conﬁrm the anti-apoptotic function of R3 in
yeloid leukemic cells we determined the expression of TRAIL
eceptors on different myeloid leukemic cell lines (Table 2). Sub-
equently, we induced 5 cell lines with distinct receptor proﬁles
able 2
RAIL receptor expression levels on 7 myeloid leukemic cell lines and sensitivity for sTR
ell death was determined by counting the 7AAD-/AnnexinV-viable cells. Nd (not done).
TRAIL R1 TRAIL R2 TRAIL R3
Percentage positive cells
ME1 (M4eo) 6 11 2
U937 (histiocytic) 10 88 6
THP1 (monocytic) 76 53 8
MM6 (monocytic) 74 93 74
HL60 (M3) 23 97 86
Kasumi (M2) 26 56 5
KG1A (M0) 50 10 5t. TRAIL-R3 expression is signiﬁcantly higher on CD34+/CD38− (which harbors the
ti-apoptotic proﬁles of leukemic blasts of 14 de novo AML patients. Analysis were
nt. Proﬁles were determined by dividing the percentage of positive leukemic blasts
L index.
with sTRAIL/Apo2L. The amount of induced cell death was deter-
mined by counting the 7AAD-/AnnexinV-viable cells. As expected
ME1 cells, that lack R1 and R2 expression, barely showed induced
cell death. U937 cells that only expressed R2 showed highest lev-
els of cell death. Cell death was reduced in MM6 cells and HL60
cells that express high levels of both R2 and R3. Although no sig-
niﬁcant correlations could be made between the expression levels
of the TRAIL receptors and the amount of induced cell death by
sTRAIL/Apo2L, these data might suggest that sTRAIL/Apo2L effects
are inhibited by binding to R3 (Table 2).
We then further explored the receptor expression on the cell
lines with high R3 expression (HL60 and MM6). TRAIL receptor
expressionwasdetermined for severaldaysonHL60andMM6cells.
Receptor expression on HL60 cells ﬂuctuated over time and turned
out to be cell cycle and differentiation status dependent [38], but
was constantly expressed on the cell surface of MM6 cells. Induc-
tion of HL60 cells on different time instants with different receptor
expression levels demonstrated a correlation (although not signif-
icant) between receptor expression deﬁned as (R1+R2)/(R3+R4)
and amount of induced cell death (p=0.08, R =−0.6). To elucidate
AIL of 5 of these cell lines. Results are the mean of at least 3 experiments. Induced

































































Fig. 6. (A) MM6 cells were treated with PI-PLC to remove R3, which is a GPI
linked protein. Treatment with PI-PLC reduces R3 >90%. Histogram is a repre-
sentative example of 3 different experiments. (B) MM6 cells treated with PI-PLC,
sTRAIL/Apo2L and Z-VAD. Results are mean of 7 different experiments. ns =not sig-46 M.E.D. Chamuleau et al. / Leu
he decoy receptor role of R3 the following experiments were per-
ormed with MM6 cells which showed stable receptor expression
evels in time.
To further elucidate the decoy receptor role of R3 we treated
M6 cells with PI-PLC. PI-PLC selectively removes GPI-linked pro-
eins from the cell surface. Among the TRAIL receptors, R3 is the
nly GPI linked protein. Treatment with PI-PLC reduces R3 efﬁ-
iently (>90%, Fig. 6A). Expression levels of the other receptorswere
ot signiﬁcantly inﬂuenced by this treatment (data not shown).
reatment with PI-PLC alone did not induce signiﬁcant cell death.
nduction with sTRAIL/Apo2L (for 18h using the same protocol as
bove) induced cell death signiﬁcantly (p=0.004, Fig. 6B). However,
irectly after removing R3, cell death could be enhanced signiﬁ-
antly when compared to induction with sTRAIL alone (p=0.001,
ig. 6B). Addition of the pancaspase inhibitor Z-VAD-fmk 1h prior
o induction with sTRAIL/Apo2L fully abrogated sTRAIL/Apo2L
nduced apoptosis indicating caspase dependent killing (with or
ithout pre-treatment with PI-PLC p=0.001).
In conclusion, these experiments strengthened our hypothesis
hat R3 has an anti-apoptotic role in myeloid cell lines.
.4. Treatment of primary AML leukemic blasts
We then treated 10 fresh primary AML samples (with dif-
erent receptor expression proﬁles) with increasing levels of
TRAIL/Apo2L (20–1000ng/ml) for 18h. Spontaneous cell death
fter 18h varied from 0 to 95%. We excluded from further anal-
sis 3 samples that showed >80% spontaneous cell death. Mean
ercentage of viable cells from the remaining samples was 69.6%
median 62.7%). Results of the remaining 7 samples are shown in
ig. 7A. sTRAIL/Apo2L induced cell death>20% in only 3 out of 7
amples (induced cell death ranged from 0 to 52% (mean 19.8%,
edian 12.9%)).
As in myeloid leukemic cells lines, no clear correlation between
he pro-apoptotic TRAIL receptor expression levels and the amount
f induced cell death by sTRAIL/Apo2L could be demonstrated in
reshly derived patient samples. However, in one patient with high
3 expression we could enhance cell death by removing R3 with
I-PLC. By adding Z-VAD we could also conﬁrm that induced cell
eath was caspase dependent (Fig. 6C).
In conclusion, despite high levels of pro-apoptotic TRAIL recep-
ors, fresh AML patient samples were not very sensitive to
TRAIL/Apo2L induced cell death, which could in some patients be
ue toahighR3expression level, aswedemonstrated inonepatient
ample that induced death could be enhanced by removal of R3.
.5. Directly targeting pro-apoptotic TRAIL receptors R1 and R2
As, in vivo, removal of R3 will also affect other GPI linked pro-
eins, we explored other ways to bypass R3 expression. We treated
ML samples with monoclonal antibodies that target speciﬁcally
1 and R2 (mapatumumab and lexatumumab, respectively) [32].
welve fresh AML samples were incubated with different concen-
rations of these antibodies (Fig. 7B and C).Mapatumumab induced
ell death >20% in only one out of twelve patients (induced cell
eath ranging from 0 to 39.2% (mean 5.9%, median 2.7%)). No clear
orrelation with R1 expression on the cell surface could be demon-
trated; the patients that showed 35% and 40% cell death had
espectively 20% and 14% R1 expression. One patient that had high
1 expression was not sensitive to mapatumumab. Lexatumumab
nduced cell death >20% in seven out of twelve patients (induced
ell death ranging from 0 to 79.6% (mean 24.1%, median 16.5%)).
or lexatumumab there was some correlation between receptor
xpression of R2 and sensitivity to the antibody; all samples that
ere sensitive to lexatumumabwerealsopositive forR2expression
>20% positive cells). However, high R2 expression did not always
niﬁcant *p=0.004, **p=0.001, ***p=0.001. (C) Fresh de novo AML sample treated
with PI-PLC and sTRAIL/Apo2L.
M.E.D. Chamuleau et al. / Leukemia
Fig. 7. (A) 7 fresh de novo AML samples were treated with increasing levels of
sTRAIL/Apo2L (20–1000ng/ml) for 18h. (B and C) 12 fresh de novo AML samples













Targeting of the pro-apoptotic receptors will be necessary to kill
these cancer stem cells although harbors the risk of targeting also1 and R2 (mapatumumab and lexatumumab).
esult in sensitivity to lexatumumab. There is no cross-reactivity
f lexatumumab or mapatumumab between the decoy receptors.
herefore the levels of decoy receptors will not affect binding or
poptosis of these antibodies. As expected, sensitivity to lexatu-
umabwas independent of R3 expression (high level of R3 did not
mpede lexatumumab induced apoptosis).
In conclusion, lexatumumab was more effective at killing pri-
ary AML cells than sTRAIL/Apo2L or mapatumumab. Sensitivity
o lexatumumab was only observed in samples that were positive
or expression of R2, but other correlations between the expression
evels of the TRAIL receptors and the sensitivity for themonoclonal
ntibodies could not be made.Research 35 (2011) 741–749 747
4. Discussion
In this studywehave evaluatedTRAIL receptor expression levels
on leukemic blasts of AML patients and compared them to receptor
expression levels on myeloid blasts of healthy donors. AML blasts
did express signiﬁcantlymore functional receptors (R1 and R2) and
signiﬁcantly lower levels of the decoy receptor R3 when compared
to myeloid blasts of healthy donors (R4 expression did not dif-
fer). This difference results in a signiﬁcantly higher pro-apoptotic
receptor proﬁle ofmyeloid leukemic blasts when compared to nor-
mal blasts of healthy donors. However, about 20% of patients have
high expression levels of the anti-apoptotic receptor R3 on their
blasts. These patients (with a relative more anti-apoptotic recep-
tor proﬁle) have a signiﬁcant shortened OS when compared to the
patients with low R3 levels and hence a more pro-apoptotic pro-
ﬁle.
As a result of the inﬂuence of TRAIL receptor expression on
OS (independent of other risk factors like cytogenetics, age and
WBC), we hypothesized that myeloid leukemic blasts are princi-
pally sensitive to TRAIL mediated killing by mTRAIL and/or sTRAIL
expressed and secreted by naturally effector immune cells as a part
of immune surveillance. Furthermore, we hypothesized that this
physiological anti-tumor activity in vivo is counteracted by high
R3 expression in a subset of patients. Upregulation of R3 could
be regarded as an expression of immune subversion, ultimately
leading to immune escape of leukemic cells. We propose that tar-
geting the TRAIL pathway could be beneﬁcial at 2 different phases
in the treatment of AML patients. First, it could be combined with
chemotherapy in the induction phase, thereby stimulating both the
intrinsic and the extrinsic apoptosis pathway. Second, aswedid not
ﬁnd a correlation between the TRAIL receptor expression and com-
plete remission rate, it could be that, in the situation of minimal
residual disease (when there is a low tumor burden) R3 positive
blasts escape immune surveillance and could also in that phase be
targeted.
Bothmyeloid leukemic cell lines and freshprimaryAMLsamples
were incubated with different concentrations of sTRAIL/Apo2L but
were not very sensitive to sTRAIL/Apo2L, that binds to all receptors.
In both cell lines and patient samples, we could not demonstrate a
signiﬁcant correlation between the expression levels of the pro-
apoptotic receptors and the amount of induced cell death. An
explanation for this phenomenon could be that sTRAIL/Apo2L is
only able to induce apoptosis if trimers of pro-apoptotic receptors
are present. It is known that also pre-assembled trimers of pro-
and anti-apoptotic receptors exist that after binding to the solu-
ble ligand will not exert apoptosis [39]. Another explanation could
be that high expression of down-stream modulators (like anti-
apoptotic molecules) prevent efﬁcient induction of cell death. We
did not study down-streammolecules. However, we could demon-
strate that removal of the decoy receptor R3 enhanced induced
cell death by soluble TRAIL both in cell lines as well as in one
patient sample. In clinical treatment, it will be difﬁcult tomodulate
R3 expression and we therefore decided to explore the possibility
of directly targeting R1 and R2, thereby bypassing R3 expression.
Myeloid blasts turned out to bemost sensitive to lexatumumab, the
antibody that selectively targets R2. Again, a correlation between
pro-apoptotic receptor expression and induced cell death could
not be demonstrated, although, R2 positivity was a requisite for
lexatumumab induced cell death. As expected, cell death was not
impeded by R3 expression. Finally, leukemic stem cells (deﬁned
by CD34+/CD38− expression) showed relative highest levels of R3.the normal hematopoietic stem cell. However, no phase I or II study
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In conclusion, our results clearly demonstrate that AML blasts
an be sensitive to cell death induction via the TRAIL receptor
athway and that R3 can function as a negative regulator of this
athway. However, it is also clear that the majority of myeloid
lasts does express pro-apoptotic receptors but fails to undergo
poptosiswhen only triggering these receptors. It is very likely that
ctivation of only the extrinsic pathway is not effective enough to
ill tumor cells that have already been shaped by the immune sys-
em. Many studies have now demonstrated synergistic activity of
TRAIL/Apo2L with conventional chemotherapy [33,40–42]. These
ffects are ascribed to the combined activation of the extrinsic and
ntrinsic apoptotic pathway. Also, synergistic effects of proteasome
nhibitors like bortezomib [29], and kinase inhibitors [25] with
TRAIL/Apo2L or TRAIL receptor antibodies have been described.
ll these data clearly demonstrate that the TRAIL pathway is an
mportant player in the complex ﬁeld of apoptosis induction of
ancer cells. We now provide evidence that the TRAIL pathway
ould be involved in immune surveillance of leukemia. Through
ypassing the decoy receptors and targeting the pro-apoptotic
RAIL receptors, apoptosis could be induced in primary AML sam-
les. Targeting the pro-apoptotic TRAIL receptors in the induction
reatment and/or in the situation ofminimal residual disease could
dd a valuable modality to the treatment of AML patients.
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